MedTrace Logo

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

NCT06471257 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 790

Last updated 2026-05-18

No results posted yet for this study

Summary

An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.

Conditions

Interventions

COMBINATION_PRODUCT

Budesonide/Albuterol metered dose inhaler, MDI

Combination Product (Drug + Device)

COMBINATION_PRODUCT

Albuterol sulfate metered dose inhaler, MDI

Combination Product (Drug + Device)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • China
  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06471257 on ClinicalTrials.gov